EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hemodialysis‐associated radioactive waste management in [ 131 I]I and [ 177 Lu]Lu radionuclide therapy

Dennis Kupitz iD, Heiko Wissel iD, Martin Volk iD, Michael C Kreissl iD, Oliver S Grosser iD

Journal of Applied Clinical Medical Physics · 2025

DOI: 10.1002/acm2.70314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Clinical Medical Physics, 2025. Verfasst von Dennis Kupitz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany. Hauptthemen laut MEDLINE: Renal Dialysis, Neuroendocrine Tumors, Iodine Radioisotopes, Octreotide. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radionuclide therapy, such as with iodine‐131 or lutetium‐177–labeled substances, is used to treat thyroid cancer and neuroendocrine tumors. Due to the incorporated radioactivity, patients must remain hospitalized until radiation levels are deemed safe, according to national regulations. This is particularly problematic for patients who require hemodialysis (HD). While contamination of dialysis waste after radionuclide therapy is generally well recognized, a critical gap remains regarding its duration and extent. This poses risks for patient management and outpatient staff.

Purpose

This study aims to demonstrate the problems with classifying residual waste and provides arguments for appropriate regulation. It evaluates if the radioactivity of the dialysate and residuals at discharge, based on whole‐body measurements, complies with relevant limits. If not, the waste is classified as radioactive and treated accordingly.

Methods

We studied four patients treated by radionuclide therapy who required dialysis: three received [ 131 I]I for thyroid disease and one [ 177 Lu]Lu‐DOTATATE for neuroendocrine neoplasia. Dialysis was performed in the nuclear medicine ward, and patients were discharged once the local dose rate limits were met. Subsequent dialysis sessions were conducted in a radiation protection area until the activity concentration in the dialysate dropped below the specific limit.

Results

Patient 1 ([ 131 I]I, thyroid cancer) showed the highest extraction rate and was discharged after 9 days, requiring nine additional dialysis sessions over 21 days. Patients 2 and 3 ([ 131 I]I, benign thyroid disease) were discharged after 8 and 4 days, with dialysis continued for 31 and 18 days under supervision, respectively. Patient 4 ([ 177 Lu]Lu‐DOTATATE) lost 4.9% of the total body radioactivity per dialysis session and was discharged after 9 days; supervised dialysis continued for 17 days.

Conclusions

This study highlights the need for refined monitoring and the limitations of standard discharge strategies for patients requiring dialysis during radionuclide therapy. Even if dose limits are met, dialysate and residuals may still require regulated handling and storage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisNeuroendocrine TumorsIodine RadioisotopesOctreotideLutetiumThyroid NeoplasmsRadioactive WasteWaste ManagementOrganometallic CompoundsHumansMaleMiddle AgedRadiotherapy DosageFemaleAgedRadiopharmaceuticalsRadioisotopes

Stichwörter der Autor:innen

hemodialysisnuclear medicineradiation protectionradionuclide therapy

Substanzen

Iodine RadioisotopesOctreotideLutetiumlutetium Lu 177 dotatateIodine-131Radioactive WasteOrganometallic CompoundsLutetium-177RadiopharmaceuticalsRadioisotopes

Autor:innen und Institutionen

  • Department for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
  • Research Campus Stimulate, Otto-von-Guericke University, Magdeburg, Germany.

ORCID-Profile: Dennis Kupitz, Heiko Wissel, Martin Volk, Michael C Kreissl, Oliver S Grosser

Zitieren

APA

Kupitz, D., Wissel, H., Volk, M., Kreissl, M. C., & Grosser, O. S. (2025). Hemodialysis‐associated radioactive waste management in [ 131 I]I and [ 177 Lu]Lu radionuclide therapy. Journal of Applied Clinical Medical Physics. https://doi.org/10.1002/acm2.70314

Vancouver

Kupitz D, Wissel H, Volk M, Kreissl MC, Grosser OS. Hemodialysis‐associated radioactive waste management in [ 131 I]I and [ 177 Lu]Lu radionuclide therapy. Journal of Applied Clinical Medical Physics. 2025. doi:10.1002/acm2.70314

BibTeX
@article{Kupitz2025,
  author = {Kupitz, Dennis and Wissel, Heiko and Volk, Martin and Kreissl, Michael C and Grosser, Oliver S},
  title = {Hemodialysis‐associated radioactive waste management in [ 131 I]I and [ 177 Lu]Lu radionuclide therapy},
  journal = {Journal of Applied Clinical Medical Physics},
  year = {2025},
  doi = {10.1002/acm2.70314}
}
Kostenlos starten →